FDA to make decision on a new CBD-based drug by the end of June


According to this Business Insider report the FDA is will be making a decision on a CBD drug. Here are 5 facts from the article.

  • A compound in marijuana that’s been linked to a range of potential health benefits — but doesn’t cause a high — is increasingly being eyed for use in salves, oils, balms, and beverages. It’s also the active ingredient in a new drug that’s on the cusp of federal approval.
  • Cannabidiol, or CBD, is estimated to make up a roughly $1 billion industry. If and when the Food and Drug Administration approves the new CBD-based drug— a decision currently slated for the end of June— it will turn the compound into one that can be legally prescribed by a doctor.
  • Since at least 2017, drug company GW Pharmaceuticals has been presenting strong research data to suggest that its CBD-based medicine, a syrup called Epidiolex, can treat the symptoms of two rare forms of childhood epilepsy that are characterized by violent seizures (known as drop seizures).
  • Although the Food and Drug Administration is not slated to make a final decision on the drug’s potential approval until June 27, experts say an official green light is likely.
  • If Epidiolex is approved, the DEA has 90 days to shift the classification of marijuana-derived CBD from the current categorization as something with “no recognized medical use” to either a Schedule 2 or 3 drug, much like the popular ADHD medication Adderall.

From the backwoods of Michigan, Thomas Dishaw is writer and health hacker. Thomas currently resides outside Philadelphia with his wife and dog. You can support Thomas' work by making a donation below or following him on Instagram. You can reach Thomas via email at tdishaw@protonmail.com.

If you found this article useful, please consider donating to fund my work.

Personal Info

Donation Total: $10.00